SCHEMBL21179876

SCHEMBL21179876

C=NNc1ccc(/C=C2/C(=O)Nc3ccccc32)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.51
MAPK1 P28482 4/20 0.51
KDR P35968 4/20 0.51
PLK4 O00444 3/20 0.51
MEN1 O00255 3/20 0.51
MAPT P10636 3/20 0.51
KMT2A Q03164 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
RET P07949 3/20 0.51
FLT3 P36888 3/20 0.51
PLK1 P53350 2/20 0.51
ALDH1A1 P00352 2/20 0.51
APP P05067 2/20 0.51
SNCA P37840 2/20 0.51
CTRC Q99895 2/20 0.51
NPC1 O15118 2/20 0.51
GMNN O75496 2/20 0.51
LMNA P02545 2/20 0.51
MTOR P42345 2/20 0.51
BLM P54132 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5478494 0.81 PDGFRB (0.62) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5478491 0.81 PDGFRB (0.62) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5481962 0.77 PDGFRB (0.72) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5481961 0.77 PDGFRB (0.72) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5476173 0.75 RAF1 (0.71) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5476171 0.75 RAF1 (0.71) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5469764 0.73 PLK4 (0.70) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL5469759 0.73 PLK4 (0.70) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL11887904 0.72 KDR (0.49) PDGFRBMAPK1KDRPLK4MEN1
SCHEMBL7397362 0.72 PDGFRB (0.57) PDGFRBMAPK1KDRPLK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47731-E1 Kinase inhibitors and method of treating cancer with same UNIV HEALTH NETWORK (CA) 2019-11-19 US disclosed
US-10358436-B2 Kinase inhibitors and method of treating cancer UNIVERSITY HEALTH NETWORK (CA) 2019-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10358436-B2 Kinase inhibitors and method of treating cancer MAP3K6, MAP3K5, MAP3K19 PDGFRB 583/4885MAPK1 55/4885KDR 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.